8-oxo-7-8-dihydrodeoxyguanine has been researched along with beta-Thalassemia* in 1 studies
1 trial(s) available for 8-oxo-7-8-dihydrodeoxyguanine and beta-Thalassemia
Article | Year |
---|---|
Clinical Laboratory Manifestation and Molecular Diagnosis of β-Thalassemia Patients in Iraq.
Many studies determined the demographic and ethnic border of patients with beta (β)-thalassemia mutations and their migration. The effective way to health care policy of β-thalassemia is to prevent homozygote births and reduce the severity of the disease. The objectives of this study contributed to investigating the molecular and serologic characteristics of β-thalassemia patients in Iraq. Peripheral blood samples were collected from 97 β-thalassemia patients and 32 healthy control subjects. Quantitative sandwich enzyme-linked immunosorbent assay was performed to measure serum ferritin, 25-hydroxy vitamin D, and 8-hydroxydeoxyguanosine (8-OHdG) levels. Further, the β-globin mutation detection assay involving an extensive screening of β-globin mutations by direct Sanger DNA sequencing and gap-PCR was performed to detect the Δ619 deletion mutation. The results revealed that compared with the control subjects, the β-thalassemia patients showed significantly decreased vitamin D levels and significantly increased serum ferritin and 8-OHdG levels (all, P<0.001). Molecular analysis detected 9 types of mutations in the β-thalassemia patients, only 2 of which, namely IVS II-1 G>A and IVS 1-5 G>C, have been previously reported in Iraqi studies, whereas the remaining 7, namely IVS-II-666 C>T, CD2 CAT>CAC, IVS-II-850 G>A, IVS-II-16 G Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Alleles; Base Sequence; beta-Globins; beta-Thalassemia; Calcifediol; Female; Ferritins; Heterozygote; Homozygote; Humans; Iraq; Male; Molecular Diagnostic Techniques; Sequence Deletion | 2020 |